A new survey conducted by a California medical marijuana delivery company has found that more patients are opting for products containing the non-psychoactive compound cannabidiol (CBD).
Eaze, a Bay-Area based cannabinoid delivery service for medical patients, recently published its second annual report, “State of Cannabis.” It reported that its patients purchased 38 percent more CBD-based cannabinoid products in 2016 compared to the year before.
CBD is the second most prominent of the more than 100 cannabinoids. Unlike the most prominent and well-known psychoactive cannabinoid tetrahydrocannabinol (THC), CBD is not psychoactive and doesn’t cause users to experience a high. CBD has been shown in a patent by the U.S. National Institutes of Health to have significant antioxidant and neuroprotective properties. Thousands of studies have been done on CBD and you can learn more about those findings here.
The Eaze report also surveyed its cannabinoid customers and found that those who purchased CBD products reported that they helped with anxiety, focus and inflammation.
CBD that is derived from marijuana is regulated under federal law and can only be legally obtained in states with medical cannabinoid laws. Patients must obtain a prescription and register with their respective state’s programs. You can learn more about the laws in your state here.
CBD that is derived from the seeds and stalk of hemp, however, is excluded from the federal Controlled Substances Act and is therefore legal to purchase under federal law, without a prescription. Individual state laws are dynamic and individual states may govern hemp-derived CBD. In most cases, however, CBD hemp oil is legally available.